Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

INCORVAIA, Lorena
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.600
EU - Europa 1.898
AS - Asia 754
SA - Sud America 20
AF - Africa 16
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 2
Totale 8.293
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.586
IT - Italia 818
SG - Singapore 315
CN - Cina 314
DE - Germania 224
FI - Finlandia 199
GB - Regno Unito 133
UA - Ucraina 133
IE - Irlanda 113
RU - Federazione Russa 53
SE - Svezia 50
RO - Romania 41
IN - India 34
BE - Belgio 32
PL - Polonia 28
HK - Hong Kong 24
NL - Olanda 16
CI - Costa d'Avorio 15
FR - Francia 15
IR - Iran 14
CA - Canada 12
BR - Brasile 10
KR - Corea 10
BG - Bulgaria 9
JP - Giappone 9
ES - Italia 8
TR - Turchia 8
CH - Svizzera 6
AT - Austria 5
AE - Emirati Arabi Uniti 4
CY - Cipro 3
CZ - Repubblica Ceca 3
EC - Ecuador 3
EU - Europa 3
PE - Perù 3
TW - Taiwan 3
AL - Albania 2
AR - Argentina 2
AU - Australia 2
CL - Cile 2
DK - Danimarca 2
GR - Grecia 2
LT - Lituania 2
MX - Messico 2
NO - Norvegia 2
UZ - Uzbekistan 2
VN - Vietnam 2
BD - Bangladesh 1
EE - Estonia 1
IL - Israele 1
IQ - Iraq 1
KG - Kirghizistan 1
KH - Cambogia 1
KW - Kuwait 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
MD - Moldavia 1
MY - Malesia 1
PH - Filippine 1
PK - Pakistan 1
SA - Arabia Saudita 1
ZA - Sudafrica 1
Totale 8.293
Salva come PNG Salva come JPEG
Città #
Fairfield 826
Chandler 578
Ashburn 537
Woodbridge 424
Houston 412
Wilmington 318
Seattle 303
Ann Arbor 278
Cambridge 256
Singapore 231
Palermo 219
Medford 132
Dublin 107
Altamura 89
Des Moines 87
Princeton 87
New York 82
San Diego 75
Ludwigshafen am Rhein 72
Lawrence 71
Jacksonville 68
Nanjing 50
Santa Clara 49
Boardman 41
Kitzingen 37
Bremen 34
Milan 34
Dearborn 33
Beijing 32
Brussels 32
Los Angeles 32
Jinan 28
London 28
Helsinki 27
Rome 26
Changsha 24
Tulsa 24
Shenyang 17
Abidjan 15
Falls Church 15
Lappeenranta 15
Aversa 14
Kumar 14
Pune 14
Nanchang 13
Washington 13
Guangzhou 12
Milazzo 12
Volla 12
Phoenix 11
Tianjin 11
Turin 11
Hebei 10
Jiaxing 10
Ningbo 10
Redwood City 10
Tehran 10
Cagliari 9
Central 9
Chicago 9
Columbus 9
Dallas 9
Munich 9
Verona 9
Izmir 8
Kilburn 8
Saint Petersburg 8
San Mateo 8
San Paolo di Civitate 8
Tappahannock 8
Council Bluffs 7
Frankfurt am Main 7
Orange 7
Seongnam 7
Bologna 6
Edinburgh 6
Mascalucia 6
Norwalk 6
Taiyuan 6
Toronto 6
Auburn Hills 5
Genoa 5
Haikou 5
Hanover 5
Hong Kong 5
Lucera 5
Moscow 5
Reggio Emilia 5
Shanghai 5
Sofia 5
Zhengzhou 5
Amsterdam 4
Florence 4
Forest City 4
Fuzhou 4
Islington 4
Kunming 4
Modena 4
Naples 4
New Bedfont 4
Totale 6.298
Salva come PNG Salva come JPEG
Nome #
Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus 199
One shot NEPA plus dexamethasone to prevent multiple-day chemotherapy in sarcoma patients 194
Gastrointestinal stromal tumors (GISTs): focus on histopathological diagnosis and biomolecular features 193
Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients 190
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 188
Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials 184
Liquid Biopsy in Breast Cancer 183
Activin A circulating levels in patients with bone metastasis from breast or prostate cancer 167
Triple negative breast cancer: Shedding light onto the role of pi3k/akt/mtor pathway 162
"Back to a false normality": New intriguing mechanisms of resistance to PARP inhibitors 159
How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis 158
Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma 155
Metastatic site location influences the diagnostic accuracy of ctDNA EGFR- mutation testing in NSCLC patients: a pooled analysis 152
Antiemetic prophylaxis containing Palonosetron (P) alone or in combination with Aprepitant (A) in the treatment of advanced soft tissue sarcoma (STS) patients with epirubicin and ifosfamide 150
Serum follistatin in patients with prostate cancer metastatic to the bone 148
Beyond evidence-based data: Scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma 148
Clinical Impact of Cystatin C/Cathepsin L and Follistatin/Activin A Systems in Breast Cancer Progression: A Preliminary Report 143
Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) 136
Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions 136
Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab 134
Activity and safety of temozolomide in advanced adrenocortical carcinoma patients 132
Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice 128
Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis 124
Surgical treatment of primary gastrointestinal stromal tumors (GISTs): Management and prognostic role of R1 resections 118
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet? 117
Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma? 114
BRCA1/2 pathogenic variants in triple-negative versus luminal-like breast cancers: genotype–phenotype correlation in a cohort of 531 patients 113
Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone? 112
MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone. 105
Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2 102
Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential 101
Liquid Biopsy in Gynecological Cancers 100
Liquid Biopsy in Gastrointestinal Stromal Tumor 100
Soft tissue sarcomas in the precision medicine era: new advances in clinical practice and future perspectives 95
Activin A and matrix metalloproteinase -2 and -9 blood levels as gauges of bone metastatic spread 94
Non-Small Cell Lung Cancer Harboring Concurrent EGFR Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma 92
New potential circulating markers for the therapeutic monitoring of metastatic bone disease. 91
Are Long Noncoding RNAs New Potential Biomarkers in Gastrointestinal Stromal Tumors (GISTs)? The Role of H19 and MALAT1 91
Studio del pattern di distribuzione dell'Activina A nel siero di pazienti con metastasi ossee da carcinoma prostatico in trattamento con acido zoledronico 89
Hereditary breast and ovarian cancer in families from southern Italy (Sicily)—Prevalence and geographic distribution of pathogenic variants in BRCA1/2 genes 87
Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives 87
ACTIVIN A CIRCULATING LEVELS IN PATIENTS WITH PRIMARY OSTEOPOROSIS OR BONE METASTASES FROM BREAST CANCER 86
Effects of zoledronic acid on proteinase plasma levels in patients with bone metastases. 86
A “lymphocyte microrna signature” as predictive biomarker of immunotherapy response and plasma pd-1/pd-l1 expression levels in patients with metastatic renal cell carcinoma: Pointing towards epigenetic reprogramming 86
Lenograstim in preventing chemotherapy-induced febrile neutropenia in patients with soft tissue sarcoma 83
Activin A circulating levels in Patients with primary osteoporosis or bone metastases from brest cancer 82
Potential miRNAs involved in molecular pathways mediating the anticancer effects of short term starvation in breast cancer cells treated with doxorubicin 82
Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib 81
Effects of Zoledronic Acid on Cathepsin K circulating levels in patients with bone metastasis. 77
Correction to: One shot NEPA plus dexamethasone to prevent chemotherapy-induced nausea and vomiting (CINV) in sarcoma patients receiving multiple-day chemotherapy (Supportive Care in Cancer, (2019), 27, 9, (3593-3597), 10.1007/s00520-019-4645-3) 77
Activin A circulating levels in patients with osteoporosis or bone metastasis from breast cancer 75
Recent advances in desmoid tumor therapy 71
Into the wild of long non-coding RNA in gastrointestinal stromal tumors (GISTs) to explore new prognostic/predictive biomarkers 66
Real-world data on cabozantinib in previously treated patients with metastatic renal cell carcinoma: Focus on sequences and prognostic factors 66
Impact of Chemotherapy in the Adjuvant Setting of Early Stage Uterine Leiomyosarcoma: A Systematic Review and Updated Meta-Analysis 66
Not all KIT 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestinal stromal tumors (GISTs) 66
How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trials 65
Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in metastatic melanoma patients? 62
Challenges and advances for the treatment of renal cancer patients with brain metastases: From immunological background to upcoming clinical evidence on immune-checkpoint inhibitors 60
null 59
I tumori stromali gastrointestinali: dalla biologia alla clinica 56
Clinical significance of Activin A serum levels in patients with primary osteoporosis: a preliminary report 54
Monoclonal antibodies for the treatment of non-hematological tumors: a safety review 53
Type and gene location of kit mutations predict progression-free survival to first-line imatinib in gastrointestinal stromal tumors: A look into the exon 53
Safety and effectiveness of gemcitabine for the treatment of classic Kaposi’s sarcoma without visceral involvement 53
Body mass index as a risk factor for toxicities in patients with advanced soft-tissue sarcoma treated with trabectedin 52
The diagnostic accuracy of PIK3CA mutations by circulating tumor DNA in breast cancer: an individual patient data meta-analysis 51
Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome 51
Cancer of the Thyroid 51
Assessment of morphological CT imaging features for the prediction of risk stratification, mutations, and prognosis of gastrointestinal stromal tumors 49
Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge 49
null 47
Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay 46
Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study 44
Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison 44
Prognostic role of plasma pd‐1, pd‐l1, pan‐btn3as and btn3a1 in patients affected by metastatic gastrointestinal stromal tumors: Can immune checkpoints act as a sentinel for short‐term survival? 43
S-Adenosylmethionine Supplementation May Reduce Cancer-Related Fatigue: A Prospective Evaluation Using the FACIT-F Questionnaire in Colon Cancer Patients Undergoing Oxaliplatin-Based Chemotherapy Regimens 41
Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors 40
Arterial Stiffness: Effects of Anticancer Drugs Used for Breast Cancer Women 39
Deep Learning Networks for Automatic Retroperitoneal Sarcoma Segmentation in Computerized Tomography 39
The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM–SIAPEC-IAP–SIBioC–SIC–SIF Italian Scientific Societies 38
Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window? 38
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study 37
Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study 36
Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies 35
Body mass index in patients treated with cabozantinib for advanced renal cell carcinoma: A new prognostic factor? 35
Molecular tumor board 33
KIT/PDGFRA Variant Allele Frequency as Prognostic Factor in Gastrointestinal Stromal Tumors (GISTs): Results From a Multi-Institutional Cohort Study 31
Exploring the potential of multiomics liquid biopsy testing in the clinical setting of lung cancer 31
The Evolving Scenario in the Assessment of Radiological Response for Hepatocellular Carcinoma in the Era of Immunotherapy: Strengths and Weaknesses of Surrogate Endpoints 31
Navigating the liquid biopsy Minimal Residual Disease (MRD) in non-small cell lung cancer: Making the invisible visible 30
Current clinically validated applications of liquid biopsy 30
Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab 29
The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIF Italian Scientific Societies 29
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group? 28
SIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations—consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM) 28
Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors 27
Mapping the landscape of immunonutrition and cancer research: A comprehensive bibliometric analysis on behalf of NutriOnc Research Group 26
The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies 26
Standard versus personalized schedule of regorafenib in metastatic gastrointestinal stromal tumors: a retrospective, multicenter, real-world study 25
Totale 8.445
Salva come PNG Salva come JPEG
Categoria #
all - tutte 46.641
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 46.641
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.157 0 0 0 0 169 224 163 114 137 130 165 55
2020/20211.332 61 51 100 93 183 87 101 92 146 162 157 99
2021/20221.264 87 186 59 28 53 70 55 69 113 162 166 216
2022/20231.686 170 306 37 217 160 245 91 143 169 33 75 40
2023/20241.184 43 127 104 112 76 181 145 122 24 65 21 164
2024/2025739 117 153 140 267 62 0 0 0 0 0 0 0
Totale 9.006